<DOC>
	<DOC>NCT00343226</DOC>
	<brief_summary>The objectives of the study are:To compare the renal function of a quadruple immunosuppressive regimen (including basiliximab in combination with an optimized cyclosporine dose during the first weeks post-transplantation, mycophenolate mofetil and corticosteroids) versus a standard triple therapy regimen (including cyclosporine standard dose, mycophenolate mofetil and corticosteroids)</brief_summary>
	<brief_title>An Open, Randomized Pilot Study to Evaluate the Use of Basiliximab With an Optimized Cyclosporine Dosing on Renal Function in "de Novo" Liver Transplantation.</brief_title>
	<detailed_description />
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Inclusion Criteria First cadaveric liver transplant ABO identical or compatible graft Exclusion Criteria Multiple organ transplant renal impairment defined as glomerular filtration rate (GFR) &lt; 30 ml/min Fulminant liver failure Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Basiliximab, transplantation, liver, renal function</keyword>
</DOC>